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ABSTRACT
Objectives and Methods: This article provides an extensive review of
literature and an in-depth analysis aimed at introducing potential applica-
tions of economic evaluation and at addressing the barriers that could
prohibit the use or diminish the usefulness of economic evaluation in Asian
settings. It also proposes the probable solutions to overcome these barriers.
Results: Potential uses of economic evaluation include the development of
public reimbursement lists, price negotiation, the development of clinical
practice guidelines, and communicating with prescribers. Two types of
barriers to using economic evaluation, namely barriers relating to the
production of economic evaluation data and decision context-related bar-
riers, are identiﬁed. For the ﬁrst sort of barrier, the development of the
national guidelines, the development of economic evaluation database,
planning and use of economic evaluation in a systematic manner, and
prioritization of topics for assessment are recommended. Furthermore,
educating potential users and the public, making the economic evaluation
process transparent and participatory, and incorporating other health
preferences into the decision-making framework have been promoted to
conquer decision context-related barriers.
Conclusions: It seems practically impossible to adopt other countries’
approaches using economic evaluation for priority setting because of
several constraints speciﬁcally related to the context of each setting. Nev-
ertheless, given a better understanding of its resistance, and proper policies
and strategies to overcome the barriers applied, it is more than probable
that a method with system/mechanisms speciﬁcally designed to ﬁt particu-
lar settings will be used.
Keywords: Asia, economic evaluation, health resource allocation, health
technology assessment, Latin America, policy decision-making.
Introduction
The question of whether it is appropriate and feasible to use
economic evaluation for policy decision-making is gaining more
interest from decision-makers in Asia [1,2]. This is because
health-care resources in every setting are always constrained
while unlimited demand is observed. This dilemma is challenging
and difﬁcult to answer because there is no country in Asia, except
South Korea, that is currently adopting economic evaluation as a
formal tool for informing health policy decisions. This article
provides an extensive review of relevant literature and an
in-depth analysis aiming to address the potential barriers that
could prohibit the use or diminish the usefulness of economic
evaluation in Asian settings. It also proposes the probable solu-
tions to overcome these barriers.
Potential Applications of Economic Evaluation
in Policy Decision-Making
This section outlines potential applications of economic
appraisal in developing policies for the rational diffusion and
use of health interventions. Although a range of policy instru-
ments for encouraging the use of this method have been
employed, and the precise use may differ from one setting to
another, the potential use of economic evaluation can be sum-
marized below.
The Development of a Beneﬁt Package for
Public Reimbursement
This may be the most popular mechanism concerning the use of
economic evidence in policy development. Several health-care
settings such as Australia, England, Wales, and Sweden have
formally adopted this approach [3,4]. In Australia, since 1993 it
has become mandatory for industry to submit economic evidence
to the Pharmaceutical Beneﬁt Advisory Committee (PBAC) if
they want their products to be in the Pharmaceutical Beneﬁt
Scheme, which is subsidized by the government [4].
Price Negotiation
Drummond et al. [5] illustrated several possible roles of eco-
nomic evaluation in drug pricing, but the obvious one was the
case of Australia, where economic data are submitted to the
PBAC for the reimbursement. Nevertheless, a price assumed in
the economic evaluation is only considered as the maximum that
the ﬁrm seeks. If the drug demonstrates good value for money the
ﬁrm may be awarded a price similar to that assumed in economic
evaluation. On the other hand, the price may be negotiated
downward based on economic evaluation and other relevant
information presented.
Development of Clinical Practice Guidelines
In England and Wales, the National Institute for Health and
Clinical Excellence (NICE) considered economic evaluation to be
a signiﬁcant input for developing practice guidelines intended to
inﬂuence health service delivery throughout the country [6]. This
situation is similar in Sweden, where members of the central
formulary committee perceived that economic evidence was
important in establishing clinical practice guidelines, although
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the members identiﬁed difﬁculties in identifying relevant eco-
nomic studies and interpreting their results [7].
Communicating with Health Professionals
It is believed that information gathering from economic evalua-
tion is useful for both public health authorities and industry to
communicate with health professionals. This is because the data
derived from economic evaluation are commonly presented in
more comprehensive forms than that reported in clinical studies.
For example, economic evaluation of osteoporosis drugs report
the effectiveness in terms of Quality Adjusted Life Year (QALY)
gained rather than fractures avoided or bone mineral density
index changed commonly used in clinical studies [8].
Barriers to the Use of Economic Evaluation in
Policy Decision-Making
Although economic evaluation is a useful rationing tool, it is far
from perfect. This section summarizes key constraints arising
from the review of literature related to the use of economic
evaluation in policy decision-making. The potential limitations
can be divided into two categories: 1) barriers related to the
production of economic information; and 2) decision context-
related barriers that include a lack of understanding of economic
evaluation among the potential users, social expectation in health
services, politics, as well as institutional, philosophical, and
ethical considerations.
Barriers Related to the Production of
Economic Information
There are a number of reasons that make economic evaluation
conducted for one setting difﬁcult to use in another setting. These
include the differences in population factors, e.g., age, gender,
socioeconomic status, and risk behaviors of populations. There
were variations of providers and health system characteristics as
well as dissimilarity in liability and incentives of remuneration
system. It has been well documented that there is a degree of
diversity regarding methodological requirements for conducting
evaluation across jurisdictions that will greatly affect the trans-
ferability of results. Although scholars proposed several solutions
to deal with variability in economic studies, the proposed
methods are not simple, and nor are they perfect; most of them
are still being developed. Therefore, developing the capacity to
conduct evaluations in a particular setting is important if eco-
nomic evidence is to be used in policy decisions in that setting.
Evidence from South Korea [9], Thailand [10], and China [2]
revealed limitations of local research capacity. The reviews found
that the numbers of economic evaluation studies within these
settings were very low compared with countries, e.g., Australia,
where economic evaluation has long been accepted for formal
use in policy decision-making [4]. This is also the case of limited
use of economic evaluation in Latin American countries [11].
The authors suggested that human resources to perform eco-
nomic evaluation in Latin America need to be increased to facili-
tate the conduct and use of the method in policy decisions.
Moreover, the reviews of economic evaluation publications in
Korea, Thailand, and China found that the majority of the
studies were vulnerable to bias because of the poor quality of
evidence used and deﬁcient reporting features. These will hinder
the adoption of the method in policy decision-making because
decision-makers prefer to use good-quality and locally relevant
information rather than international data.
Furthermore, the use of economic evaluation could be pro-
hibited if it is not available at the right time for making decisions
[12]. Alongside scarce research capacities, different operational
cultures between decision-makers and researchers also play a
vital role. The Thai study found that decision-makers often work
in a very tight time frame; therefore, they are unlikely to be able
to wait long for evidence [13]. Decisions often need to be made
and action taken when windows of opportunity open. Neverthe-
less, researchers prefer to work within a longer time frame
because they want to ensure a perfect study. Economic evaluation
will have a limited impact on policymaking if the evidence is
available when the intervention has been well established.
Because once an intervention becomes widely acceptable among
practitioners, restriction of its use will be very difﬁcult.
Given resource constraints, it is necessary that economic
evaluations themselves are being prioritized and are focusing on
interventions that would assist decisions targeting major health
problems that could subsequently have a large impact on popu-
lation health [14]. In spite of this fact, a review of literature in
Thailand shows an absence of economic evaluation publications
for 15 of the top 20 major health problems of the Thais [10].
This poor distribution of researches directed toward major
health problems could be explained by the relationship between
funding sources and the distribution of economic evaluations by
disease category. For example, the majority of studies funded by
international nonproﬁt organizations focused merely on diar-
rhea, malaria, and vaccine-preventable diseases. These were not
major health problems of the country but were of particular
interest to those organizations. This similar situation was also
found in Malaysia where majority of studies on cost-effectiveness
and cost–beneﬁt were funded by pharmaceutical companies [2].
The problem of studies not focusing on vital health concerns will
deﬁnitely diminish the usefulness of economic evaluation in
policy decision-making.
Furthermore, although the guidelines for conducting eco-
nomic evaluation are available in most developed countries, only
a few guidelines exist in developing countries [2]. At present,
South Korea, China, Taiwan, and Thailand are the only nations
having their own guidelines [15]. The absence of a standard
methodology in most countries is one of the major barriers that
diminish the use of economic results because the guidelines will
increase the transparency of the evaluations undertaken by
allowing stakeholders to assess the appropriateness of the
methods and the quality of evidence used.
Decision Context-Related Barriers
These barriers differ from the ones above because they are related
closely to the users’ knowledge, attitudes, and perceptions
regarding the use of economic evaluation. The following para-
graphs describe each of these barriers.
Lack of understanding of economic evaluation among potential
users. There have been concerns about the absence of a clear
understanding of economic evaluation among potential users in
many settings. Ikegami et al. [16] stated that economic evalua-
tion was a new discipline among health professionals and
decision-makers in Japan, and only a few of them were aware of
the technique as their main focus was on biomedical sciences,
with little or no interest shown in the social and economic aspects
of health care. A similar problem also happened in Korea and
Thailand where there was limited knowledge and understanding
of concepts and applications of economic evaluation among
decision-makers. The study in Thailand found that decision-
makers misused terminology and often failed to distinguish
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between cost analysis and economic evaluation [13]. Yang et al.
observed a large variation of knowledge and understanding of
economic evaluation among staff at a health authority respon-
sible for reviewing the cost-effectiveness and budget impact data
of newly entering drugs for the National Health Insurance Cor-
poration in Korea [17].
Social expectation in health care. The public anticipates that
health care perform based on the best interest of patients[18]. It
is unlikely that the general public would be willing to leave
someone to suffer without help just because the intervention
available to him or her does not present good value for money
[19]. This expectation could easily create conﬂict in making
health technology coverage decisions if economic evaluation,
which concerns collective health beneﬁts, is to be used. A survey
of decision-makers and academics in Thailand found that more
than 70% of respondents did not agree to exclude a life-saving
intervention from a health beneﬁt package just because it was
cost-ineffective [20].
Politics. Resource allocation is inherently political, and it has
become evident that politics will inevitably inﬂuence the use of
economic evaluation for resource allocation. A case in point,
Thai decision-makers perceived themselves to be the losers if
economic evaluation were to be used for making decisions
because their power and authority would be transferred to “sci-
entists” [13]. Moreover, health professionals of the Japanese
Medical Association considered that there might be a loss of
clinical autonomy if the method was used for health-care ration-
ing. As a result, the organization’s position is clearly opposed to
the economic/efﬁciency concept [16]. In settings where economic
evaluation has been used it is clearer that political considerations
can play a major role in the coverage process. This is the case in
the selection process for the technologies to be appraised by
NICE and the development of clinical guidelines for trastuzumab
(Herceptin) [21].
Social institutional barriers. Given that social institutions are, in
essence, a set of repeated behaviors that are driven by social
norms, values, and rules, they inﬂuence decision-makers by
encouraging them to choose an option that is most conducive to
the norms and values that are linked to their institutional afﬁli-
ations and the achievement of their organization’s goal(s). In
Thailand, institutional factors seem to inﬂuence all stakeholders’
use of economic evaluation for making coverage decisions with
different directions. The use of economic evaluation would
ideally support the institutional ideology of both hospital direc-
tors (to improve efﬁciency and to control costs) and academics
(to use explicit criteria that are accepted by them) but not the
institutional modes of conduct and interests of professional insti-
tutions and health workers (to maintain their clinical autonomy)
[13]. For decision-makers at the Ministry of Public Health, the
use of economic evaluation alone would not be enough to serve
the institutional interests because there are other strong consid-
erations such as total budget size, equity, social solidarity, and
protection against catastrophic health expenditure [22].
The early development of modern health-care services in
many countries in Asia were closely associated with royal patron-
age or volunteer Christian doctors from Western countries who
worked for nonproﬁt organizations. Although the health-care
systems have undergone successive evolutions, the health profes-
sional communities still have strong traditions, and they are
reluctant to explicitly discuss economic aspects but prefer to
maintain their public image that they act only on the basis of
profession and altruism. Without doubt, it is not common for
health professionals and their associations to consider value for
money of services to which they offered their patients or would
conﬂict with their professional ethics.
Philosophical and ethical considerations. It is apparent that utili-
tarianism, on which economic evaluation is based, is not the only
ethical principle that can be used to make a justiﬁed health
resource allocation. Teerawattananon and Russell [20] demon-
strated that philosophical and ethical considerations are complex
and multifaceted, especially when decisions have to be made
between providing life-saving/cost-ineffective interventions and
non-life-saving/cost-effective interventions. Many decision-
makers, health professionals, and academics rejected the QALY
maximization principle by supporting life-saving (but cost-
ineffective) renal dialysis rather than the more cost-effective
laparoscopic cholecystectomy, which would have resulted in
more QALYs for the same amount of resources used [20].
Utilitarianism may not be very popular in Asia where the
Buddhist philosophy strongly inﬂuences the way of thinking. The
“Middle-Way” in which the Buddha referred to avoiding
the extremes of sensual indulgence and self-mortiﬁcation as the
proper way to live is clearly contradicted by the QALY maximi-
zation concept. In this situation, if people wanted their health-
care system to make people live as long as or as well as possible
(to maximize QALYs) then they were only causing themselves to
increase their cravings or wants. On the other hand, if people
follow the middle path by requesting that the health-care system
offers services that they think are reasonable (even if sometimes
the service may not be the best possible) or allow very old people
to die, then people will ﬁnd themselves a lot happier because they
are able to overcome their cravings for life at any cost.
In addition, Asian people give a very high value and respect to
the elderly. As a result, they may prefer to allocate resources for
a cost-ineffective intervention to those with old age rather than to
offer a cost-effective treatment to the young. These above
examples will clearly restrict the use of economic evaluation in
health-care decision-making.
Potential Solutions to Facilitate the Use of
Economic Evaluation in Decision-Making
Based on the aforementioned barriers, this section offers practical
guidance to improve the use of economic evaluation. Seven rec-
ommendations are proposed to overcome these barriers and also
help guide users and supporters of economic evaluation toward
the most effective use of the method in policy and practice.
Standardization of Economic Evaluation Methods
In response to the problem of poor quality of economic evalua-
tion available for decision-making there is a need for a set of
methodological guidelines that will facilitate the use of standard
methods and a high quality of evidence for studies. A uniform
methodology will increase the transparency of studies by allow-
ing readers or users to assess precisely what the analysts have
done and whether the method was appropriate [23]. Further-
more, these guidelines will ensure standards that enable compari-
sons of value for money across health interventions. This is the
case because the difference in a cost-effectiveness ratio is likely to
reﬂect true differences between the interventions being evaluated
rather than differences in study methodology [10].
Making Economic Evaluation Available at the
Right Time
Two ways to improve the availability of information for decision-
making in a timely fashion are suggested. First, economic evalu-
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ations should be planned and used formally, as requirement by
the law, rather than on an ad hoc basis. It is possible for eco-
nomic evaluations to be conducted and used as routine informa-
tion, for example, for the pharmaceuticals listed in Australia
[24], or they can be used with a clear time line for evaluations, as
is the practice by NICE [25].
Second, the development of an economic evaluation database
is crucial in assisting its users to gain better access to reliable
information for competing health technologies [26]. Although
there are a number of international databases that include eco-
nomic evaluation literature, they usually include only evaluations
published in academic journals and in English [27]. Nevertheless,
many economic evaluations conducted in several settings, espe-
cially in developing countries, have been published in grey litera-
ture, e.g., theses or research reports and using local languages.
This makes it more difﬁcult for the review [26].
Prioritization of Topics for Assessment
It is necessary that economic evaluations focus on interventions
to improve decision-making, although decisions regarding the
prioritization of investment in economic evaluations do not have
to be based purely on disease burden. This is the case because to
be worthwhile, there have to be available and proven effective
interventions and/or opportunities for studies to add their values
into policy decisions. Here the recommendations, modiﬁed from
Goodman [28] and Sassi [29], state that topics for assessment
should be in line with one or more of the following key concerns:
1. interventions that will cause a signiﬁcant increase in health
expenditure, or a signiﬁcant budgetary burden, or a poor
return on investments, or interventions that will drain a
high level of resources from other interventions;
2. interventions likely to offer signiﬁcant improvement in
health outcomes but have not been widely accepted;
3. interventions likely to have signiﬁcant adverse effects in
terms of health outcomes, ethical implications, and organi-
zational impact;
4. interventions likely to have a socially undesirable redistri-
bution of resources or health outcomes.
Educating Decision-Makers and Health Professionals
Because of a lack of understanding of economic evaluation
among potential users, the users will face challenges in commu-
nicating with the public about its use in policy decisions [13].
Economic evaluation is only likely to be used if the users have the
capacity to use it and to explain it to others. Therefore, it is
necessary to educate the users about the method and for them to
become conﬁdent in interpreting the evidence.
Educating the Public
The need to raise public awareness regarding the fact that health-
care resources are limited and that rationing is inevitable is surely
the right thing to do because it is apparent that decision-makers
are sensitive to the interests of the public. Decision-makers are
reluctant to support the use of economic evaluation because it is
difﬁcult for them to explain to the public their reasons for not
providing care [13].
If the public were well educated about the economic evalua-
tion, they may accept or reject the method. But at the very least,
public awareness will increase public trust in the decision-making
process. It is possible that the public might accept the limitations
of resources and the use of economic evaluation. It should be
noted that the general public has fewer political and institutional
barriers than politicians. If the public accepts the use of economic
evaluation, it will be easier and more legitimate to adopt the
method for decision-making.
Making the Economic Evaluation Processes Transparent
and Participatory
Transparency in conducting economic evaluations is a major
concern for all stakeholders in every setting. Both public and
private payers usually want to be involved in the evaluation
process to ensure that the studies are done in a transparent way
and achieve a high standard. To do this it is recommended that
stakeholders are involved from the beginning, i.e., setting and
ﬁne-tuning the research questions. While the study is being con-
ducted, stakeholders can be involved as input experts to inform
and verify information used in the study. At the end, it is also
necessary that the preliminary results are presented to these
stakeholders to validate the ﬁndings and collectively formulate
policy recommendations [30].
Incorporating Other Health Preferences into the
Decision-Making Framework
The QALY maximization concept of economic evaluation is not
the only goal in health-care resource allocation [31]. Equity,
necessity (severity of disease), social solidarity, and protection
against catastrophic expenditure also play a signiﬁcant role [32].
In proposing the use of economic evaluation, it is not necessarily
the case that other criteria concerning resource allocation must
be eliminated. Economic evaluation can be supplemented with
equity, solidarity, and economic security criteria to enhance the
political and public acceptance of a health-care package. There-
fore, it would be interesting to see an alternative approach for
economic evaluation that incorporates other resource allocation
criteria.
Conclusion
There are potential areas for the use of economic evaluation for
policy development. Nevertheless, empirical evidence from Asian
and Latin American countries suggests that using economic
evaluation for decision-making appears to be more complicated
than is commonly presumed to be the case. Two types of poten-
tial barriers to using economic evaluation, namely barriers relat-
ing to the production of economic evaluation data and decision
context-related barriers, have been identiﬁed in this article. It is
necessary to distinguish between these two barriers when the
feasibility of using economic evaluation is considered. To achieve
a substantial increase in the impact of economic evaluation in
decision-making, different strategies are needed to overcome the
barriers.
It is noteworthy that the barriers and solutions addressed in
this article may not be completely generalizable across health-
care settings because of differences in health-care infrastructures,
human resource capacities, institutions, and incentives as well as
social, political, and ethical factors inherent in each health-care
system. Nevertheless, this article provides a wider and more
comprehensive view in looking at potential barriers and solutions
that can be applied to assess the feasibility and facilitate the use
of economic evaluation or other resource allocation criteria in
other settings. It also raises concerns regarding the importance of
developing health-care infrastructures and human resources for
evidence-based policy decision-making.
Lastly, it seems practically impossible to adopt economic
evaluation using either Australian or European styles for setting
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priority in the likes of Asian countries because there are several
constraints speciﬁcally related to the context of each health-care
system. The ideological and normative values of society concern-
ing health resource allocation may greatly differ betweenWestern
and oriental settings. Resources and infrastructures for conduct-
ing economic evaluation are more limited in Asia compared with
those in Western countries. As a consequence, each health-care
setting needs to initiate its own system/mechanisms for the use of
economic evidence for prioritizing health resources. Given a
better understanding of the resistance to the use of economic
evaluation, and proper policies and strategies to improve the
feasibility and acceptance of using economic evaluation, it is
more than probable that economic evaluation will be used for
guiding policy decisions instead of the imprecise, inconsistent,
and unaccountable practice of health-care prioritization, which
still exists in many health-care systems in Asia.
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